HBM and Umoja Biopharma Forge Strategic Alliance to Advance Multiple In Vivo CAR-T Cell Therapies

　　【Pharmaceutical Network Industry DynamicsOn November 5, 2025, the announcement of Harbour BioMed's wholly-owned subsidiary Nona Biologics deepening its strategic cooperation with Umoja Biopharma attracted industry attention. The two parties decided to deeply integrate Nona Biologics' HCAb Harbour Mice platform and NonaCarFxTM platform with Umoja Biopharma’s VivoVecTM platform to jointly advance the development of multiple in vivo CAR-T cell therapy products.
 

As a core component of Harbour BioMed's technology matrix, the HCAb Harbour Mice platform is a globally scarce cornerstone for fully human antibody development. This platform overcomes the limitations of high immunogenicity and low efficiency in traditional models through transgenic technology, enabling the simultaneous generation of fully human heavy-chain antibodies (HCAb) and classic two-chain antibodies (H2L2). The molecular weight of heavy-chain antibodies is only half that of conventional antibodies, maintaining strong antigen recognition capabilities while offering enhanced tissue penetration and resolving light chain mispairing issues. These unique advantages provide an inherent edge in the development of bispecific, multispecific, and CAR-T complex molecules. To date, it has supported Harbour BioMed (Suzhou) Co., Ltd. in collaborating on over 300 projects with more than 110 global partners, with 19 molecules advancing into clinical development stages. Meanwhile, the NonaCarFxTM platform, as a specialized technological achievement by Harbour BioMed (Suzhou) Co., Ltd. in the CAR-T field, focuses on precise optimization and functional enhancement of CAR structures. Through modular design of targeting domains and signaling domains, it significantly improves CAR-T cell tumor recognition specificity, in vivo persistence, and cytotoxic activity, forming a "antibody discovery - cell engineering" technological closed loop with the HCAb platform.
 

Complementing this, the VivoVecTM platform is the core weapon for Umoja Biopharma to solve the challenge of in vivo CAR-T delivery. As an advanced in vivo gene delivery technology, it uses an optimized lentiviral vector system to directly deliver CAR-encoding genes into T cells within the patient’s body, enabling in situ modification and activation of T cells without the need for ex vivo cell extraction and culture processes. Supporting this technology is Umoja Biopharma's state-of-the-art lentiviral vector development and manufacturing facility located in Colorado, USA, which has the capability to produce high-quality vectors at scale, providing a solid foundation for technology translation. Compared with traditional ex vivo CAR-T therapies, the VivoVecTM platform not only significantly shortens the treatment cycle but also reduces production costs through a standardized delivery system, laying the groundwork for improving the accessibility of immunotherapy.
 

Under the collaborative support of the three major platforms, Harbour BioMed has established a promising in vivo CAR-T R&D pipeline. Leveraging high-specificity targeting antibodies screened through the HCAb Harbour Mice platform and combining the CAR structure optimization technology of the NonaCarFxTM platform, the company has laid out multiple R&D directions for hematologic malignancies and solid tumors. Among these, the candidate product targeting CD19-positive hematologic malignancies has completed preliminary target validation, with its fully human heavy-chain antibody targeting domain showing reduced immunogenicity; the pipeline targeting Claudin18.2-positive solid tumors utilizes the tissue penetration advantages of heavy-chain antibodies to address the challenge of insufficient CAR-T cell infiltration in solid tumor treatment. These pipelines are all planned to use the VivoVecTM platform for in vivo delivery and have entered the preclinical evaluation stage, with an anticipated IND submission by 2026. Notably, Harbour BioMed's pipeline layout continues its "platform-driven" strategic feature, allowing all candidate products to achieve rapid optimization through iterative advancements across the three platforms, showcasing high flexibility and innovation.
 

Behind this technical collaboration lies the enormous development potential of the in vivo CAR-T market. Since the world's first CAR-T therapy was approved in 2017, this "living drug" has demonstrated significant efficacy: after treatment, the overall response rate for patients with relapsed or refractory large B-cell lymphoma is approximately 80%, and 40%-60% of patients achieve long-term survival of more than five years. However, issues such as long manufacturing cycles, high production costs, and limited patient applicability severely restrict the clinical popularization of traditional ex vivo CAR-T therapies—CAR-T products already on the market in China are generally priced at millions of yuan, mainly covering hematological tumors. The emergence of in vivo CAR-T therapy precisely addresses these pain points. Market research shows that the global CAR-T therapy market size will exceed $11 billion by 2025 and is expected to soar to $190 billion by 2034, with in vivo CAR-T predicted to occupy half of the market. In the Chinese market, Frost & Sullivan forecasts that the CAR-T market size will reach 28.9 billion yuan by 2030, with unmet needs in solid tumors being particularly prominent. For instance, there are 360,000 new cases of gastric cancer annually, providing vast application opportunities for in vivo CAR-T.
 

From the perspective of the industry's competitive landscape, the technical barriers formed by this collaboration are highly competitive. Currently, most companies globally involved in in vivo CAR-T focus on breakthroughs in single technical aspects, whereas the combination of Harbour BioMed (Suzhou) Co., Ltd and Umoja Biopharma has achieved full-chain coverage from "antibody discovery - CAR design - gene delivery." The fully human advantage of the HCAb Harbour Mice platform can reduce drug immunogenicity, the structural optimization capability of the NonaCarFxTM platform enhances efficacy, and the delivery technology of the VivoVecTM platform ensures accessibility. The synergistic "1+1+1>3" effect generated by these three platforms is expected to give the collaborative products a comprehensive advantage in safety, efficacy, and cost-effectiveness. Additionally, Harbour BioMed has previously established collaborations with international leaders such as AstraZeneca and Pfizer through a technology licensing model, with cumulative cooperation amounts exceeding tens of billions of dollars. This open collaborative ecosystem lays the foundation for the global commercialization of future products.
 

For patients, the successful implementation of in vivo CAR-T therapy will shift cancer treatment from "personalized customization" to "standardized treatment." Patients will no longer need to wait for prolonged cell preparation processes, enabling immediate drug administration. Treatment costs at the million-yuan level are also expected to significantly decrease through technological iteration, making it affordable for more ordinary patients. Particularly in the field of solid tumor treatment, with the advancement of in vivo CAR-T product research targeting Claudin18.2, GPC3, and other targets, there is hope to provide new treatment options for patients with high-incidence cancers such as gastric cancer and liver cancer, filling the current gap in clinical treatment.
 

From the terms of the agreement, Nanobody (Suzhou) Co., Ltd. will receive an upfront payment, option payment, and milestone payments, while Umoja Biopharma will be responsible for subsequent development and commercialization. As the collaboration progresses, the integration of the three platforms' technologies may lead to more innovative therapies and even extend into areas such as autoimmune diseases, further enhancing market value.
 

Disclaimer: This article is generated by AI. In any case, the information or opinions expressed in this article do not constitute investment advice to any person.